GRAPPA Network

Directions Website Contact the organisation

GRAPPA Network Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from GRAPPA Network, Nonprofit Organization, London.

GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) has pulled together many different groups, including over 1,000 preeminent researchers and thought-leaders in psoriatic arthritis (PsA) and psoriasis (PsO) worldwide.

🌟 Trainee Abstract Poster Highlight from the GRAPPA Trainee Symposium at the 2026 Annual Meeting in Lisbon 🌟Alina Feng f...
09/10/2026

🌟 Trainee Abstract Poster Highlight from the GRAPPA Trainee Symposium at the 2026 Annual Meeting in Lisbon 🌟

Alina Feng from University of California, United States, presented the following poster:

"Decreased risk of psoriatic and inflammatory arthritis in patients with psoriasis initiating treatment with glucagon-like peptide-1 receptor agonists"

Lay Summary: Psoriatic arthritis is a painful and irreversible form of arthritis that can develop in people with psoriasis and lead to permanent joint damage if left untreated. The risk is higher in those with obesity or type 2 diabetes, suggesting that improving metabolic health may also have a role in reducing the risk of developing arthritis. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are medications commonly used to treat obesity and diabetes, but their association with psoriatic and inflammatory arthritis risk remains unclear.

We analyzed health records from a large national database to compare people with psoriasis who started a GLP-1RA with comparators who did not receive these medications. We then followed both groups over time to determine the risk of developing psoriatic or inflammatory arthritis.

In this study, those who received a GLP-1RA were less likely to develop psoriatic arthritis and other inflammatory arthritis than those who did not receive these medications. This lower risk was observed across patients with obesity, type 2 diabetes, or were male or female, and with newer GLP-1RAs such as semaglutide and tirzepatide.

These findings suggest that GLP-1RAs may help reduce the risk of developing inflammatory arthritis in people with psoriasis. While part of this benefit may be related to weight loss and improved metabolic health, GLP-1RAs may also have direct anti-inflammatory effects. Additional studies are needed to determine whether these medications can help prevent psoriatic arthritis and better understand how they may influence disease progression.

Congratulations to Alina on this exciting work and thank you for contributing to the future of psoriatic disease research!

🎉 Please join us in welcoming Iulia-Simona Chirică as a new GRAPPA member!Simona is a rheumatology resident at Dr. Ion C...
08/10/2026

🎉 Please join us in welcoming Iulia-Simona Chirică as a new GRAPPA member!

Simona is a rheumatology resident at Dr. Ion Cantacuzino Clinical Hospital and a PhD student at Carol Davila University of Medicine and Pharmacy in Bucharest, Romania.

Her clinical and research interests focus on psoriatic arthritis, particularly neuropathic-like and nociplastic pain, patient-reported outcomes, and the impact of persistent pain on patients’ daily lives.

Welcome to GRAPPA, Dr. Simona Chirică! 👏

🔎 What were the key psoriatic disease abstracts presented at EADV 2026?GRAPPA is bringing together expert faculty on Oct...
07/10/2026

🔎 What were the key psoriatic disease abstracts presented at EADV 2026?

GRAPPA is bringing together expert faculty on October 14 for our EADV Virtual Congress Highlights.

Join us as we revisit research presented in Vienna, highlight key abstracts in psoriatic disease, and discuss important findings from this year’s Congress.

Whether you attended EADV in person or followed from afar, this virtual program is an opportunity to catch up on research you may have missed.

📅 October 14, 2026 | Virtual

Register now: https://smpl.is/andvt

🌟 Trainee Abstract Poster Highlight from the GRAPPA Trainee Symposium at the 2026 Annual Meeting in Lisbon 🌟Arabi Rasend...
07/10/2026

🌟 Trainee Abstract Poster Highlight from the GRAPPA Trainee Symposium at the 2026 Annual Meeting in Lisbon 🌟

Arabi Rasendrakumar from University of Toronto, Canada, presented the following poster:

"Complex, Difficult-to-Manage, and Treatment-Refractory Psoriatic Arthritis:​ Application of GRAPPA and EULAR Definitions in a Large Observational Cohort"

Lay Summary: Psoriatic arthritis (PsA) is a chronic condition that causes joint pain, swelling, and can also affect the skin. While many people improve with treatment, some continue to have active disease despite trying several medications. These patients are often described as having “difficult-to-manage (D2M),” “complex-to-manage (C2M),” and/or “treatment-refractory (TR)” PsA. Two major expert groups (GRAPPA and EULAR) have recently proposed definitions to help identify these patients, but it is unclear how these approaches compare in real-world practice.

In this study, we examined 630 adults with PsA receiving care at a large clinic in Toronto. Using these definitions, about 36% of patients were classified as C2M by GRAPPA, compared with about 19% classified as D2M by EULAR. Around 13% of patients were considered treatment-refractory by both definitions. Patients in the TR group had more active disease, higher levels of inflammation, and greater exposure to advanced therapies.

We also found that women and individuals with higher body weight were more commonly represented in these difficult-to-treat groups. Overall, the GRAPPA definition identified a larger group of patients, while the EULAR definition was more stringent. Despite these differences, both approaches successfully identified patients with a higher disease burden.

These findings highlight the importance of recognizing challenging PsA cases and may help guide more personalized and multidisciplinary care strategies.

Congratulations to Arabi on this exciting work and thank you for contributing to the future of psoriatic disease research!

👏 We’re excited to introduce Nga Lori Ly as a new member of the GRAPPA community!Based in Utah, United States, Lori is a...
06/10/2026

👏 We’re excited to introduce Nga Lori Ly as a new member of the GRAPPA community!

Based in Utah, United States, Lori is an Advanced Practice Provider with University of Utah Health’s Division of Rheumatology, where she has 10 years of specialized clinical experience. Her clinical and research work focuses on psoriatic disease and spondyloarthritis, with particular interests in improving access to care, research participation, and treatment for patients with psoriatic arthritis.

We’re thrilled to have Lori join our growing global community and look forward to her involvement with GRAPPA! 🌎

🌟 Trainee Abstract Poster Highlight from the GRAPPA Trainee Symposium at the 2026 Annual Meeting in Lisbon 🌟Giacomo Cozz...
30/09/2026

🌟 Trainee Abstract Poster Highlight from the GRAPPA Trainee Symposium at the 2026 Annual Meeting in Lisbon 🌟

Giacomo Cozzi from Università di Padova, Italy, presented the following poster:

"Comparative early ultrasound changes across TNF, JAK, IL-17 and IL-23 inhibition in Psoriatic Arthritis"

Lay Summary: Psoriatic arthritis is a chronic inflammatory disease that can affect the joints, tendons and entheses, which are the sites where tendons and ligaments attach to bone. Several targeted treatments are available, but they work through different biological pathways and may not act with the same speed on musculoskeletal inflammation.

In this real-world study, we evaluated patients with active psoriatic arthritis who were starting or switching a biologic or targeted synthetic treatment. Patients received TNF inhibitors, JAK inhibitors, IL-17 inhibitors or IL-23/IL-12/23 pathway inhibitors. We used musculoskeletal ultrasound to measure inflammation over time, focusing on pragmatic ultrasound scores called MIJET and 2MIJET. These scores are designed to capture inflammatory changes in clinically relevant joint, entheseal and tendon sites.

The main aim was to compare how quickly ultrasound inflammation improved across the different treatment classes. Overall, ultrasound monitoring showed that early changes were clinically informative. Patients who maintained treatment over time had greater improvement in MIJET and 2MIJET during follow-up than those who discontinued treatment. Baseline ultrasound burden alone was less useful, while dynamic ultrasound changes were more informative.

When comparing treatment classes, JAK inhibitors showed the fastest early ultrasound improvement, particularly at 1 month. TNF, IL-23 and IL-17 inhibitors showed more gradual early changes.

These findings suggest that musculoskeletal ultrasound may help detect early differences in treatment response across mechanisms of action. Pragmatic ultrasound scores could complement clinical assessment and support short-term treatment monitoring in patients with psoriatic arthritis.

Congratulations to Giacomo on this exciting work and thank you for contributing to the future of psoriatic disease research!

What an incredible morning at EADV 2026 in Vienna! 🎉We were thrilled by the tremendous turnout for today’s GRAPPA Sympos...
30/09/2026

What an incredible morning at EADV 2026 in Vienna! 🎉

We were thrilled by the tremendous turnout for today’s GRAPPA Symposium, with Hall C packed and standing room only for a morning of learning and discussion focused on psoriatic disease.

A huge thank you to our outstanding faculty and speakers for sharing their expertise, insights, and latest research and to everyone who joined us and helped make this session such a success.

We are grateful to see so much enthusiasm and engagement from the global dermatology community. Thank you, Vienna! 👏

📣 Register Now: GRAPPA EADV Virtual Congress HighlightsJoin GRAPPA on October 14 for a virtual look at key research and ...
30/09/2026

📣 Register Now: GRAPPA EADV Virtual Congress Highlights

Join GRAPPA on October 14 for a virtual look at key research and abstracts in psoriatic disease presented this week at the 2026 EADV Congress in Vienna.

Our expert faculty will highlight important findings from the Congress and share their perspectives on the latest research impacting the field.

📅 October 14, 2026
💻 Virtual

Mark your calendar and join the GRAPPA community as we bring the highlights of EADV directly to you!

Register now: https://smpl.is/an7gd

📣Now Available: Young GRAPPA’s Do not Miss Highlights in Psoriatic Disease at EADV.Young GRAPPA has created a curated se...
29/09/2026

📣Now Available: Young GRAPPA’s Do not Miss Highlights in Psoriatic Disease at EADV.

Young GRAPPA has created a curated selection of abstracts on psoriatic disease to be presented this week at EADV in Vienna, categorized by basic science, clinical topics, and treatment highlights.

Explore what’s new, what’s relevant, and what deserves your attention.

Read now at https://smpl.is/an7b5

🌟 Trainee Abstract Poster Highlight from the GRAPPA Trainee Symposium at the 2026 Annual Meeting in Lisbon 🌟Dimitrios De...
25/09/2026

🌟 Trainee Abstract Poster Highlight from the GRAPPA Trainee Symposium at the 2026 Annual Meeting in Lisbon 🌟

Dimitrios Deligeorgakis from Hippokration Hospital, Greece, presented the following poster:

"Biologic DMARD class influences progression from psoriasis to PsA: A real-world cohort study"

Lay Summary: Psoriasis is a long-term skin condition, and some people with psoriasis later develop psoriatic arthritis, which causes pain, swelling, and stiffness in the joints. Finding ways to prevent this progression is an important goal.

In this study, we looked at almost 400 people with psoriasis who were treated with different types of biological medicines over a period of up to 17 years. None of the participants had arthritis when they started treatment. We compared how often people developed psoriatic arthritis while receiving different biological treatments.

We found that people treated with medicines that target the immune proteins IL-17 or IL-23 were less likely to develop psoriatic arthritis than those treated with medicines that target TNF. These findings were consistent across several different analyses designed to test the reliability of the results. We did not find meaningful differences between the non-TNF treatments.

Because this was an observational study, it cannot prove that one treatment directly prevents arthritis. However, the results suggest that the choice of biological treatment for psoriasis may influence the future risk of developing psoriatic arthritis.

Further studies, including prospective clinical trials, are needed to confirm whether some biological treatments can help prevent psoriatic arthritis in people with psoriasis and to identify which patients are most likely to benefit.

Congratulations to Dimitrios on this exciting work and thank you for contributing to the future of psoriatic disease research!

Address

London

Website

Alerts

Be the first to know and let us send you an email when GRAPPA Network posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organisation

Send a message to GRAPPA Network:

Shortcuts

Sponsored

Share

Category